FDA Panel To Weigh Adequacy Of Efficacy Evidence For Kalydeco Label Expansion
This article was originally published in The Pink Sheet Daily
Executive Summary
Vertex is seeking approval for cystic fibrosis patients ages six years and older with the R117H mutation despite the pivotal trial’s primary endpoint failure and unfavorable pediatric subgroup results. Company believes totality of evidence supports approval and pediatric efficacy can be extrapolated from positive adult subgroup findings.
You may also be interested in...
Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year
Kalydeco, an oral CFTR potentiator, becomes the first approved drug to address the underlying cause of cystic fibrosis, rather than just treating the disease’s symptoms.
ACIP Shies Away From COVID-19 Vaccine Comparative Efficacy And Safety Evaluations
The CDC panel’s mandate is to make recommendations for each specific vaccine brought forward, not ‘comparing two, three or four vaccines, and coming up with specific recommendations for each one independent of the other,’ chairman Jose Romero says as ACIP recommends use of Janssen’s COVID-19 vaccine under EUA.
ACIP Shies Away From COVID-19 Vaccine Comparative Efficacy And Safety Evaluations
The CDC panel’s mandate is to make recommendations for each specific vaccine brought forward, not ‘comparing two, three or four vaccines, and coming up with specific recommendations for each one independent of the other,’ chairman Jose Romero says as ACIP recommends use of Janssen’s COVID-19 vaccine under EUA.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: